Amgen and AstraZeneca Launch HORIZON Study: A New Hope for Pediatric Asthma Treatment

Amgen and AstraZeneca's HORIZON study is evaluating the efficacy and safety of tezepelumab in pediatric patients with severe uncontrolled asthma. The study, which began in August 2023 and is expected to complete in 2025, involves subcutaneous injections and compares tezepelumab to a placebo. A positive outcome could expand Amgen and AstraZeneca's portfolio in pediatric asthma treatments and potentially influence their stock performance positively.

Amgen Inc (AMGN) and AstraZeneca (AZN) have announced an update on their ongoing clinical study, HORIZON, which aims to evaluate the efficacy and safety of tezepelumab in pediatric patients with severe uncontrolled asthma. The study, initiated on August 24, 2023, is expected to complete by the end of 2025 [1].

The HORIZON study is a Phase 3, randomized, double-blind, placebo-controlled trial that compares the biological intervention tezepelumab to a placebo. Tezepelumab is administered via subcutaneous injections and is being tested to manage severe asthma in children aged 5 to 12 years. The study is designed to provide insights into the therapeutic potential of tezepelumab, addressing an unmet medical need in this demographic [1].

The clinical trial follows a triple-masking design, ensuring that participants, care providers, and investigators are unaware of the treatment allocations. The primary purpose of the study is treatment-focused, with the goal of assessing the efficacy and safety of tezepelumab in managing severe asthma in children [1].

The study began in August 2023 and is currently recruiting participants. The last update was submitted on August 5, 2025, indicating ongoing progress and commitment to this research. The study is listed on the ClinicalTrials portal for further details [1].

A positive outcome from the HORIZON study could expand Amgen and AstraZeneca's portfolio in pediatric asthma treatments. This could potentially influence their stock performance positively, especially if interim results show promising outcomes. The study's significance lies in its potential to provide a new treatment option for children with severe uncontrolled asthma, setting a competitive edge in the respiratory treatment market [1].

References:
[1] https://www.tipranks.com/news/company-announcements/amgen-and-astrazenecas-horizon-study-a-new-hope-for-pediatric-asthma